Lithium (Li) is the first GSK3β inhibitor to be identified and widely used in prescription medicine for bipolar disorder treatment (King et al., 2014), and SB216763 has been widely used in GSK3β-related studies and has been found to improve memory impairment, stimulants-induced hyperactivity, behavioral sensitization, and synaptic transmission dysfunction (Xu et al., 2011; Zhao et al., 2016; Lin et al., 2018). The gene discussed is GSK3B; the disease is memory impairment.